Atea Pharmaceuticals, Inc. (AVIR) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 20, 2025, discloses the results of Atea Pharmaceuticals, Inc.'s 2025 Annual Meeting of Stockholders. The meeting was held on the same date, with a record date of May 8, 2025. Approximately 87.6% of the company's outstanding common stock was represented at the meeting.
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. No financial statements or metrics are included in this document.
Material Changes and Voting Results
The filing details the final voting results for three proposals:
- Proposal 1 (Election of Directors): Three Class II directors were elected to serve until the 2028 annual meeting.
- Bruno Lucidi: 46,640,587 FOR; 12,559,084 WITHHOLD; 15,781,736 BROKER NON-VOTE.
- Polly Murphy, DVM, PhD: 41,184,263 FOR; 18,015,408 WITHHOLD; 15,781,736 BROKER NON-VOTE.
- Bruce Polsky, MD, MACP, FIDSA: 46,597,653 FOR; 12,602,018 WITHHOLD; 15,781,736 BROKER NON-VOTE.
- Proposal 2 (Auditor Ratification): Ratification of KPMG LLP as the independent registered public accounting firm for the year ending December 31, 2025.
- Result: 73,766,274 FOR; 1,192,659 AGAINST; 22,474 ABSTAIN. Proposal Approved.
- Proposal 3 (Executive Compensation): Advisory approval of named executive officer compensation.
- Result: 46,450,302 FOR; 12,107,029 AGAINST; 642,340 ABSTAIN; 15,781,736 BROKER NON-VOTE. Proposal Approved.
Guidance, Outlook, and Risks
This filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. It strictly reports the outcome of the shareholder vote.
Key Facts for Investor Verification
- Verify the total number of shares outstanding as of the May 8, 2025 record date to confirm the 87.6% attendance calculation.
- Note the significant number of "Broker Non-Votes" (15,781,736) on the director election and executive compensation proposals, indicating brokers did not have discretionary authority to vote on these matters.
- Confirm the tenure of the newly elected directors (Class II) extends through the 2028 annual meeting.
- Review the definitive proxy statement (Schedule 14A) filed on April 29, 2025, for detailed biographies of the directors and the rationale for the executive compensation package.